These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12616501)

  • 21. CD8(+) T cells specific for beta cells encounter their cognate antigens in the islets of NOD mice.
    Pang S; Zhang L; Wang H; Yi Z; Li L; Gao L; Zhao J; Tisch R; Katz JD; Wang B
    Eur J Immunol; 2009 Oct; 39(10):2716-24. PubMed ID: 19658094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4+ T-cell-independent rejection of corneal allografts.
    Niederkorn JY; Stevens C; Mellon J; Mayhew E
    Transplantation; 2006 Apr; 81(8):1171-8. PubMed ID: 16641604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells.
    Nishimura E; Sakihama T; Setoguchi R; Tanaka K; Sakaguchi S
    Int Immunol; 2004 Aug; 16(8):1189-201. PubMed ID: 15237110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of CD4+ and CD8+ T cells in murine skin and heart allograft rejection across different antigenic desparities.
    Youssef AR; Otley C; Mathieson PW; Smith RM
    Transpl Immunol; 2004 Dec; 13(4):297-304. PubMed ID: 15589743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation.
    Fehr T; Takeuchi Y; Kurtz J; Wekerle T; Sykes M
    Eur J Immunol; 2005 Sep; 35(9):2679-90. PubMed ID: 16082727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
    Cheadle EJ; Hawkins RE; Batha H; Rothwell DG; Ashton G; Gilham DE
    J Immunother; 2009 Apr; 32(3):207-18. PubMed ID: 19242379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
    Cui Y; Kelleher E; Straley E; Fuchs E; Gorski K; Levitsky H; Borrello I; Civin CI; Schoenberger SP; Cheng L; Pardoll DM; Whartenby KA
    Nat Med; 2003 Jul; 9(7):952-8. PubMed ID: 12778137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific tolerance induction of allo-K(b)-skin grafts by FK506 in the CD8-depleted H-2(k) recipients required low amounts of K(b)-antigen.
    Chen BG; Liu Z; Wu Y
    Transpl Immunol; 2005 Oct; 15(1):9-16. PubMed ID: 16223668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity.
    Lin CT; Chang TC; Shaw SW; Cheng PJ; Huang CT; Chao A; Soong YK; Lai CH
    Vaccine; 2006 Sep; 24(37-39):6199-207. PubMed ID: 16824651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
    Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.
    Cohen PA; Peng L; Plautz GE; Kim JA; Weng DE; Shu S
    Crit Rev Immunol; 2000; 20(1):17-56. PubMed ID: 10770269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
    Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.